The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer.

von Deimling, Markus; Mertens, Laura S; Furrer, Marc; Li, Roger; Tendijck, Guus A H; Taylor, Jacob; Crocetto, Felice; Maas, Moritz; Mari, Andrea; Pichler, Renate; Moschini, Marco; Tully, Karl H; D'Andrea, David; Laukhtina, Ekaterina; Del Giudice, Francesco; Marcq, Gautier; Velev, Maud; Gallioli, Andrea; Albisinni, Simone; Mori, Keiichiro; ... (2024). The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer. BJU international, 134(1), pp. 119-127. Wiley 10.1111/bju.16319

Preview

Text BJU_International_-_2024_-_Deimling_-_The_optimal_number_of_induction_chemotherapy_cycles_in_clinically_lymph_node_positive.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (764kB) | Preview

OBJECTIVE

To investigate the optimal number of induction chemotherapy cycles needed to achieve a pathological response in patients with clinically lymph node-positive (cN+) bladder cancer (BCa) who received three or four cycles of induction chemotherapy followed by consolidative radical cystectomy (RC) with pelvic lymph node dissection.

PATIENTS AND METHODS

We included 388 patients who received three or four cycles of cisplatin/gemcitabine or (dose-dense) methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), followed by consolidative RC for cTanyN1-3M0 BCa. We compared pathological complete (pCR = ypT0N0) and objective response (pOR = yp ≤T1N0) between treatment groups. Predictors of pCR and/or pOR were assessed using uni- and multivariable logistic regression analysis. The secondary endpoints were overall (OS) and cancer-specific survival (CSS). We evaluated the association between the number of induction chemotherapy cycles administered and survival outcomes on multivariable Cox regression.

RESULTS

Overall, 101 and 287 patients received three or four cycles of induction chemotherapy, respectively. Of these, 72 (19%) and 128 (33%) achieved pCR and pOR response, respectively. The pCR (20%, 18%) and pOR (40%, 31%) rates did not differ significantly between patients receiving three or four cycles (P > 0.05). The number of cycles was not associated with pCR or pOR on multivariable logistic regression analyses. The 2-year OS estimates were 63% (95% confidence interval [CI] 0.53-0.74) and 63% (95% CI 0.58-0.7) for patients receiving three or four cycles, respectively. Receiving three vs four cycles was not associated with OS and CSS on uni- or multivariable Cox regression analyses.

CONCLUSION

Pathological response and survival outcomes did not differ between administering three or four induction chemotherapy cycles in patients with cN+ BCa. A fewer cycles (minimum three) may be oncologically sufficient in patients with cN+ BCa, while decreasing the wait for definitive local therapy in those patients who end up without a response to chemotherapy. This warrants further validation.

Interest & Impact

Downloads

15 since deposited on 14 Mar 2024
15 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item